This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
by Zacks Equity Research
Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys are part of the Zacks top Analyst Blog.
Can Exact Sciences (EXAS) Climb 55.43% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 55.4% upside potential for Exact Sciences (EXAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.
Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y
by Zacks Equity Research
Robust revenues from Exact Sciences' (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 49.06% and 2.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag
by Zacks Equity Research
Halozyme's (HALO) fourth-quarter 2023 earnings meet estimates, while revenues miss the same.
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
by Zacks Equity Research
Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.
Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi
by Zacks Equity Research
The FDA grants accelerated approval to Iovance's (IOVA) Amtagvi (lifileucel) for treating advanced melanoma after anti-PD-1 and targeted therapy. Stock rises.
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates
by Zacks Equity Research
Agios' (AGIO) earnings and revenues miss estimates in the fourth quarter of 2023. Revenues from its sole marketed drug, Pyrukynd, rise year over year.
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
by Zacks Equity Research
Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.
C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Exact Sciences' (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer screening tests, Cologuard and Oncotype DX.
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Advances in Cancer Research With New Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) subsidiary Haystack Oncology collaborates with TriSalus Life Sciences to improve therapeutic options for aggressive forms of cancer.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Oncology Space Gains Momentum: 3 Stocks in Focus
by Zacks Equity Research
Stocks such as EXAS, DGX and LH are likely to potentially continue the momentum in the oncology field.
Moderna (MRNA) Moves 13.1% Higher: Will This Strength Last?
by Zacks Equity Research
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
5 Impressive MedTech Industry Growth Stocks to Buy for 2024
by Moumi Mondal
Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.
Exact Sciences' (EXAS) Solid Cologuard Sales, Innovation Aid
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.
Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS), driven by growth in Screening and Precision Oncology segments.
Why Is Exact Sciences (EXAS) Up 2.5% Since Last Earnings Report?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
If You Invested $1000 in Exact Sciences a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
by Zacks Equity Research
Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.
Wall Street Analysts See a 51.73% Upside in Exact Sciences (EXAS): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 51.7% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.